The Online Investor
Daily M&A
Contrarian Outlook
Stock Option Ideas
Preferred Stock Newsletter
Biotechnology M&A image Biotechnology M&A » By The Online Investor Staff, updated Wed., May. 5, 7:53 PM Recent mergers and acquisitions in the Biotechnology M&A category.

Slide #24. Myriad Genetics Crescendo Bioscience

Acquirer: Myriad Genetics (NASDAQ:MYGN)
Acquiree: Crescendo Bioscience
Details: Safeguard Scientifics, Inc. (NYSE:SFE) today announced that its partner company, Crescendo Bioscience, Inc. ("Crescendo"), signed an amended agreement to be acquired by Myriad Genetics, Inc. (NASDAQ:MYGN) for $270 million, in cash, minus $25 million for the repayment of a loan made to Crescendo by Myriad in 2011 and subject to further adjustment for Crescendo's cash, other indebtedness, working capital and other amounts to be determined in accordance with the acquisition agreement. The transaction is expected to close in the fiscal quarter ending March 31, 2014, pending satisfactory completion of customary closing conditions and regulatory approval. Safeguard expects to receive approximately $40 million in aggregate cash proceeds pending final closing calculations. Safeguard has deployed $11 million in Crescendo since December 2012 and has a 13% primary ownership position.

Myriad Genetics is precision medicine company acting as an advisor to transform patient lives through molecular diagnostics. Co.'s molecular diagnostic tests are designed to analyze genes, their expression levels and corresponding proteins to assess an individual's risk for developing disease later in life, diagnose disease, determine a patient's likelihood of responding to a particular drug, or disease recurrence and assess a patient's risk of disease progression. Co. also provides biomarker discovery and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries utilizing its multiplexed immunoassay technology.

MYGN SEC Filing Email Alerts Service

Open the MYGN Page at The Online Investor »

Company Name:  Myriad Genetics, Inc.
Stock buyback:  MYGN buyback
Sector:  Biotechnology
Number of ETFs Holding MYGN:  45
Total Market Value Held by ETFs:  $624.12M
Total Market Capitalization:  $2.32B
% of Market Cap. Held by ETFs:  26.91%

Open the MYGN Page at The Online Investor (in a new window) »

May 5, 2021    7:53 PM Eastern
Quotes delayed 20 minutes

Hold (1.50 out of 4)
0th percentile
(ranked lower than approx. 100% of all stocks covered)

Analysts' Target Price:
MYGN Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Biotechnology M&A - Slide 24 of 83 | | Copyright © 1998 - 2021, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.